FDA Cleared New Software for Ceribell System

The new FDA clearance adds advanced EEG analysis features to the Ceribell monitoring platform.

Updated on Sept. 30, 2026 in Stroke

FDA Cleared New Software for Ceribell System

Live Poll

Do you believe new AI-powered diagnostic tools improve the quality of care in local hospitals?

The FDA granted 510(k) clearance for new software capabilities on the Ceribell System, a platform that combines portable hardware with AI-powered algorithms. This update is designed to simplify bedside EEG interpretation and support faster clinical decision-making.

Why it matters

By transforming raw EEG data into simple, actionable trends at the bedside, the technology aims to improve the speed and accuracy of neurological assessments in a clinical setting. The clearance notably carries no age restrictions for patients, expanding the potential utility of the system.

The FDA clearance grants the system 3 new capabilities, including Alpha-Delta Ratio, Relative Alpha trending, and Burst Suppression monitoring. These tools expand upon previous approvals for neonatal seizure detection and delirium assessment.

The players

FDA

The Food and Drug Administration is the federal agency responsible for regulating medical devices and ensuring their safety and effectiveness in the United States.

Ceribell

Ceribell is a medical technology company based in Sunnyvale, California, that specializes in rapid response EEG monitoring systems.

The details

The platform functions by converting raw EEG input into accessible trends, allowing clinicians to perform quantitative trending and amplitude-integrated EEG analysis without specialized interpretation overhead. These features are intended to streamline the workflow for medical teams monitoring brain activity.

September 30, 2026: The FDA granted 510(k) clearance to the Ceribell software.
First half of 2027: Ceribell plans to release an automatic software update with the new features.

The Big Picture

The new software update represents a broader industry shift toward integrating AI algorithms directly into portable medical diagnostic platforms. This clearance extends the functionality of the existing Ceribell System by adding advanced quantitative analysis tools to its established hardware platform.

The approval allows clinicians to use these advanced monitoring tools for patients of all ages, facilitating faster bedside evaluations. By simplifying complex EEG analysis, the software helps medical teams make more efficient treatment decisions for patients in critical condition.

The takeaway

Advancements in automated EEG trending reflect a move toward faster, more accessible brain monitoring in emergency and critical care settings. These tools provide clinicians with clearer data to assist in rapid diagnostics for neurological patients.